CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Convalescent Plasma from COVID-19 donorsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Investigational- Compassionate Use of Convalescent Plasma From COVID-19 Donors in Oncological and Non-Oncological Patients With Severity Criteria: FALP 001-2020 Trial (FALP-COVID)

COVID-19 infection has spread worldwide causing several deaths in few months Convalescent Plasma from COVID 19 donors has shown huge activity in small series from Chinese patients and currently many centers from USA and the European Union are assessing its use looking to avoid mortality and prolonged hospitalizations COVID-19-related

NCT04384588 COVID-19 Infection Cancer Patients General Population Biological: Convalescent Plasma from COVID-19 donors
MeSH:Infection

Primary Outcomes

Description: in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma

Measure: in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma

Time: 1 year

Description: safety of convalescent plasma from COVID 19 donors (CTCAE V5.0)

Measure: safety of the use of convalescent plasma drom COVID 19 donors

Time: 1 year

Secondary Outcomes

Description: any cause of mortality during these periods

Measure: Mortality at 30 days, 90 days, 6 months and 1 year

Time: 1 year

Description: based on results from this trial comparing with official information

Measure: in-hospital Mortality COVID-19 related compared with non-treated population according to Chilean official reports

Time: through study completion, an average of 1 year

Description: number of days of hospitalization in high complexity facilities after convalescent plasma use

Measure: Number of days of hospitalization in high complexity facilities after convalescent plasma use

Time: 1 year

Description: number of days of hospitalization in intensive care unit after convalescent plasma use

Measure: Number of days of hospitalization in intensive care unit after convalescent plasma use

Time: 1 year

Description: number of days of mechanical ventilatory support in patients after convalescent plasma use

Measure: Number of days of mechanical ventilatory support in patients after convalescent plasma use

Time: 1 year

Description: total number of days of mechanical ventilatory support

Measure: Total number of days of mechanical ventilatory support

Time: 1 year

Description: total number of hospitalization days in patients treated with convalescent plasma

Measure: Total number of hospitalization days in patients treated with convalescent plasma

Time: 1 year

Description: total number of hospitalization days in patients after treatment with convalescent plasma

Measure: Number of hospitalization days in patients after treatment with convalescent plasma

Time: 1 year

Description: Viral load measuring

Measure: Viral load measuring

Time: 14 days

Description: COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies

Measure: Immunological response in treated patients (COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies)

Time: day 1 of hospitalization

Description: negativization of COVID 19 load since convalescent plasma use

Measure: Negativization of COVID 19 load since convalescent plasma use

Time: 14 days

Description: negativization of COVID 19 load since hospitalization

Measure: Negativization of COVID 19 load since hospitalization

Time: 14 days

Description: negativization of COVID 19 load since first reported symptoms COVID-19 related

Measure: Negativization of COVID 19 load since first reported symptoms COVID-19 related

Time: 14 days

Description: Interferon Gamma measurement from donor

Measure: Donor Interferon Gamma profile characterization

Time: 1 day

Description: Granulocyte Macrophage Colony Stimulating Factor measurement from donor

Measure: Donor Granulocyte Macrophage Colony Stimulating Factor characterization

Time: 1 day

Description: Tumor Necrosis Factor Alfa measurement from donor

Measure: Donor Tumor Necrosis Factor Alfa characterization

Time: 1 day

Description: Interleukin -1 beta measurement from donor

Measure: Donor Interleukin -1 beta characterization

Time: 1 day

Description: Interleukin -2 measurement from donor

Measure: Donor Interleukin-2 characterization

Time: 1 day

Description: Interleukin -4 measurement from donor

Measure: Donor Interleukin-4 characterization

Time: 1 day

Description: Interleukin -6 measurement from donor

Measure: Donor Interleukin-6 characterization

Time: 1 day

Description: Interleukin -8 measurement from donor

Measure: Donor Interleukin-8 characterization

Time: 1 day

Description: Interleukin -10 measurement from donor

Measure: Donor Interleukin-10 characterization

Time: 1 day

Description: Interferon Gamma measurement from receptor

Measure: Receptor Interferon Gamma profile characterization

Time: 1 day

Description: Granulocyte Macrophage Colony Stimulating Factor measurement from receptor

Measure: Receptor Granulocyte Macrophage Colony Stimulating Factor characterization

Time: 1 day

Description: Tumor Necrosis Factor Alfa measurement from receptor

Measure: receptor Tumor Necrosis Factor Alfa characterization

Time: 1 day

Description: Interleukin -1 beta measurement from receptor

Measure: receptor Interleukin -1 beta characterization

Time: 1 day

Description: Interleukin -2 measurement from receptor

Measure: Receptor Interleukin-2 characterization

Time: 1 day

Description: Interleukin -4 measurement from receptor

Measure: Receptor Interleukin-4 characterization

Time: 1 day

Description: Interleukin -6 measurement from receptor

Measure: Receptor Interleukin-6 characterization

Time: 1 day

Description: Interleukin -8 measurement from receptor

Measure: Receptor Interleukin-8 characterization

Time: 1 day

Description: Interleukin -10 measurement from receptor

Measure: Receptor Interleukin-10 characterization

Time: 1 day


No related HPO nodes (Using clinical trials)